Last reviewed · How we verify

NCT06292546

The Effects of High-dose Dual Therapy With Probiotics on Gut Microbiota for Helicobacter Pylori Rescue Treatment

Completed NA Last updated 13 May 2025
What this trial tests

NA trial testing Vonoprazan in Gut Microbiota in 72 participants. Completed in 28 February 2025.

Timeline
31 January 2024
Primary endpoint
30 December 2024
28 February 2025

Quick facts

Lead sponsorZhongshan Hospital (Xiamen), Fudan University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment72
Start date31 January 2024
Primary completion30 December 2024
Estimated completion28 February 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Zhongshan Hospital (Xiamen), Fudan University

Who can join

Adults 18 to 65, any sex, with Gut Microbiota or Metabolic Disturbance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to evaluate the effects of High-dose Dual therapy combined with probiotics on the gut microbiota for Helicobacter pylori rescue treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Vonoprazan

Trials testing the same drug.

Other recruiting trials for Gut Microbiota

Currently open trials in the same condition.

Other Zhongshan Hospital (Xiamen), Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06292546.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing